Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 785461, 8 pages
http://dx.doi.org/10.1155/2015/785461
Research Article

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer

1Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland
2Institute of Surgical Pathology, University Hospital, University of Zurich, 8091 Zurich, Switzerland
3Institute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland

Received 1 August 2015; Accepted 27 September 2015

Academic Editor: Felix Chun

Copyright © 2015 Marian S. Wettstein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Aims. CD73 is a membrane associated 5′-ectonucleotidase that has been proposed as prognostic biomarker in various solid tumors. The aim of this study is to evaluate CD73 expression in a cohort of patients with primary bladder cancer in regard to its association with clinicopathological features and disease course. Methods. Tissue samples from 174 patients with a primary urothelial carcinoma were immunohistochemically assessed on a tissue microarray. Associations between CD73 expression and retrospectively obtained clinicopathological data were evaluated by contingency analysis. Survival analysis was performed to investigate the predictive value of CD73 within the subgroup of pTa and pT1 tumors in regard to progression-free survival (PFS). Results. High CD73 expression was found in 46 (26.4%) patients and was significantly associated with lower stage, lower grade, less adjacent carcinoma in situ and with lower Ki-67 proliferation index. High CD73 immunoreactivity in the subgroup of pTa and pT1 tumors was significantly associated with longer PFS (HR: 0.228; ) in univariable Cox regression analysis. Conclusion. High CD73 immunoreactivity was associated with favorable clinicopathological features. Furthermore, it predicts better outcome in the subgroup of pTa and pT1 tumors and may thus serve as additional tool for the selection of patients with favorable prognosis.